NCT03807804 - Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 14, 2021

Study Completion Date

December 14, 2021

Conditions

Respiratory Distress Syndrome, Adult

Interventions

BIOLOGICAL

HLCM051

HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.

Trial Locations (29)

Unknown

Investigational Site Number 027, Nagoya

Investigational Site Number 028, Nagoya

Investigational Site Number 005, Seto

Investigational Site Number 020, Toyoake

Investigational Site Number 003, Hirosaki

Investigational Site Number 007, Iizuka

Investigational Site Number 019, Ōgaki

Investigational Site Number 011, Sapporo

Investigational Site Number 010, Kobe

Investigational Site Number 013, Kobe

Investigational Site Number 017, Takarazuka

Investigational Site Number 025, Yokohama

Investigational Site Number 029, Yokohama

Investigational Site Number 018, Kashihara

Investigational Site Number 026, Suita

Investigational Site Number 022, Ōtsu

Investigational Site Number 014, Izumo

Investigational Site Number 024, Bunkyō-Ku

Investigational Site Number 021, Chuo Ku

Investigational Site Number 009, Itabashi-ku

Investigational Site Number 006, Minato-Ku

Investigational Site Number 004, Shinagawa-Ku

Investigational Site Number 008, Shinjuku-Ku

Investigational Site Number 023, Shinjuku-Ku

Investigational Site Number 012, Hiroshima

Investigational Site Number 001, Kumamoto

Investigational Site Number 002, Kyoto

Investigational Site Number 015, Nagasaki

Investigational Site Number 016, Saga